UNH Stock Today Falls 3% as Profit Drops 41% — Is the Selloff Overdone?

UnitedHealth Group (NYSE: UNH) sank again in today’s session, with the stock last shown around $273.77, down $8.57 or -3.04% (market open, as of 2:54:56 PM EST). The move extends a stretch of underperformance that investors have increasingly linked to one theme: profitability pressure.

That pressure is visible in the latest operating snapshot being discussed across markets. UnitedHealth reported a sharp 41.1% drop in adjusted operating earnings even as revenue rose 15.7%, a divergence that has reignited debate over whether the selloff has gone too far or is still repricing a new margin reality.

Today’s market read-through

UNH’s decline has stood out versus the broader tape. While the overall market was up 0.71%, the healthcare sector slipped 0.38% — and UNH fell roughly 2.98% on the latest read, underscoring that company-specific concerns are dominating daily price action. A recent intraday dip of -2.64% has also been cited as part of this continued pressure.

Profitability squeeze shaping sentiment

The key issue is margin compression tied to higher medical costs and reduced Medicare funding, factors that have weighed on UnitedHealthcare’s performance and outlook. Investors have also focused on weakness in Medicare Advantage dynamics, including the expectation that 2026 could see 1.3 million to 1.4 million fewer members, alongside funding-cut concerns in Medicaid. Together, these factors have become the narrative center for why UNH has been unable to stabilize despite its scale.

Guidance tone adds to caution

UnitedHealth’s full-year 2026 revenue outlook of $439 billion is being framed as a key negative surprise because it sits about $15 billion below Wall Street projections shared in market commentary. That gap has amplified concerns that operational challenges are not a one-quarter story. At the same time, the company expects a rebound in operating earnings in 2026, a counterpoint that bullish investors are watching closely for confirmation in upcoming updates.

Price performance shows the scale of the reset

UnitedHealth remains a mega-cap, with a market capitalization cited around $255.8 billion, and it still sits at the center of the U.S. health insurance ecosystem through its health plans and Optum platform. But the stock has absorbed a dramatic rerating:

• -53.4% from the 52-week high of $606.36 reached on Apr. 11, 2025
• -11.5% over the past three months
• -14.5% year-to-date
• -38.8% over the past 52 weeks

Over the same comparison window often cited by traders, the Dow Jones Industrials benchmark was up 5.5% over the last three months, with returns of 1.5% year-to-date and 12.4% over the past year — reinforcing how sharply UNH has lagged.

Technical picture remains heavy

Technicians have pointed to a persistent bearish structure. UNH has traded below its 50-day moving average since late October 2025 (with only brief fluctuations) and has remained below its 200-day moving average across much of the past year. For many momentum investors, that combination signals that rallies may continue to face overhead resistance until fundamentals improve or the trend shifts decisively.

Quarterly catalyst that accelerated the selloff

The market reaction to earnings remains a key reference point. On Jan. 27, UNH shares closed down 19.6% after the Q4 release. Adjusted EPS came in at $2.11, edging above the $2.09 consensus expectation, while revenue was reported at $113.2 billion versus a $113.3 billion forecast. Even with an EPS beat, the combination of revenue softness and forward caution intensified investor skepticism around margins and funding headwinds.

Valuation rerating fuels the “overdone” argument

One reason the “selloff overdone” debate has gained traction is valuation compression. UNH’s P/E ratio was cited as falling from 32.18x in Q4 2024 to 17.78x in Q3 2025. A fair value estimate referenced in market commentary sits at $486.86, implying the stock could be roughly 42% undervalued based on that framework.

Analysts, meanwhile, have maintained a broadly constructive stance: UNH holds a consensus “Moderate Buy” rating from 26 analysts, with a mean price target near $361.43 — implying about 28% upside from current levels.

Insider activity shows routine tax-related selling

Market watchers have also noted a cluster of insider transactions. On Feb. 13, 2026, five senior officers executed tax payment-related share dispositions totaling $325,009.32, each at $293.19 per share. Individual transactions ranged from $36,829.36 to $94,374.05, with an average value of about $65,001.86. The participants listed included leaders across Optum and UnitedHealthcare, the EVP & Chief People Officer, EVP & Chief Legal Officer, and the Chief Accounting Officer. The activity was described as routine with no anomalies flagged.

Long runway, uneven near-term execution

UnitedHealth’s scale still matters. Based in Minnetonka, Minnesota, the company operates across managed care and healthcare services, offering a range of coverage options including HMOs, POS, PPOs, and managed fee-for-service programs. In parallel, the broader healthcare finance solutions market has been cited as growing at a projected 8.2% CAGR, a backdrop that supports the long-term thesis for well-positioned incumbents.

For now, the stock’s path continues to revolve around two questions investors are pricing in real time: whether medical cost trends normalize fast enough, and whether Medicare funding and enrollment trends stop eroding profitability. If operating earnings do rebound in 2026 as anticipated, the gap between the current price and bullish targets becomes easier to justify. If pressures persist, today’s decline may be the market’s way of demanding clearer proof — not promises — that margins are stabilizing.

For company updates and official disclosures, you can review UnitedHealth Group’s Investor Relations. For broader Medicare program context, see the Centers for Medicare & Medicaid Services.